×
  • Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Blood Screening Market Share

    ID: MRFR/MED/5434-HCR
    85 Pages
    Rahul Gotadki
    October 2025

    Blood Screening Market Research Report By Technology (Nucleic Acid Amplification Test, Enzyme-Linked Immunosorbent Assay, Next-Generation Sequencing), Product and Services (Reagents, Instruments) and End User (Hospitals and Clinics) - Forecast till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Blood Screening Market Infographic
    Purchase Options
    Compare License
    Summary Table of Contents Segmentation Download PDF

    Market Share

    Blood Screening Market Share Analysis

    The significance of being a critical component in healthcare has made it so competitive that firms always want higher shares among them. One common strategy used by most firms is differentiating their products from those offered by rivals. This might involve coming up with new technologies through which more accurate diagnostics can be done, like inventing one's biomarkers for use during such tests. Another strategy adopted by key players in this market is cost leadership. By focusing on operational efficiency and economies of scale, businesses can reduce their production costs and offer competitive prices for blood screening services. This has led to the rising popularity of their products among consumers, especially healthcare providers who are always on a budget, thereby increasing their market shares. The blood screening industry is affected by market positioning through strategic partnerships and collaborations. To widen their scope and reach out to new markets, companies may form unions with healthcare facilities, laboratories, or research groups. Another blood screening marketing share-increasing tactic involves expanding geographically. This will enable the corporation to target customers that were hitherto unreachable in such a manner. The expansion may require changing products and services to suit specific regional needs and regulatory requirements. In so doing, organizations make a stronger presence and increase the overall market share. Brand development, together with advertising, also plays an important role in defining a firm's market rate in the blood screening industry. Good brand building creates faithfulness among doctors as well as end users. To have a good image of the brand, firms must demonstrate that they have efficient blood screening services that are accurate when it comes to results obtained. To maintain or extend one's already acquired market share in the blood screening sector, customer-centric strategies are vital. With the aim of better suiting them, companies strive to understand the ever-changing requirements of health providers and labs that purchase their product range. Good customer service provision coupled with training courses related to those services and constant updates of the product based on clients' suggestions results in the satisfaction of these clients, thus ensuring retention.

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Get In Touch

    Leave a Comment

    FAQs

    What is the projected market valuation of the Blood Screening Market by 2035?

    The Blood Screening Market is projected to reach approximately 9.898 USD Billion by 2035.

    What was the market valuation of the Blood Screening Market in 2024?

    In 2024, the Blood Screening Market was valued at 3.4 USD Billion.

    What is the expected CAGR for the Blood Screening Market during the forecast period 2025 - 2035?

    The expected CAGR for the Blood Screening Market during the forecast period 2025 - 2035 is 10.2%.

    Which technology segment is anticipated to show significant growth in the Blood Screening Market?

    The Nucleic Acid Amplification Test segment is expected to grow from 1.2 USD Billion in 2024 to 3.5 USD Billion by 2035.

    What are the key products and services driving the Blood Screening Market?

    Reagents and instruments are key products, with reagents projected to grow from 1.5 USD Billion in 2024 to 4.5 USD Billion by 2035.

    Which end-user segment is likely to dominate the Blood Screening Market?

    Hospitals are likely to dominate the end-user segment, growing from 1.7 USD Billion in 2024 to 4.8 USD Billion by 2035.

    Market Summary

    As per MRFR analysis, the Blood Screening Market Size was estimated at 3.4 USD Billion in 2024. The Blood Screening industry is projected to grow from 3.747 USD Billion in 2025 to 9.898 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 10.2 during the forecast period 2025 - 2035.

    Key Market Trends & Highlights

    The Blood Screening Market is poised for substantial growth driven by technological advancements and increasing health awareness.

    • Technological advancements in blood screening are enhancing diagnostic accuracy and efficiency, particularly in North America.
    • The Asia-Pacific region is emerging as the fastest-growing market, fueled by rising healthcare investments and infrastructure improvements.
    • Nucleic Acid Amplification Tests dominate the market, while Next-Generation Sequencing is rapidly gaining traction as a preferred method.
    • Key market drivers include the increasing prevalence of infectious diseases and rising awareness of blood donation and screening initiatives.

    Market Size & Forecast

    2024 Market Size 3.4 (USD Billion)
    2035 Market Size 9.898 (USD Billion)
    CAGR (2025 - 2035) 10.2%
    Largest Regional Market Share in 2024 North America

    Major Players

    <p>Abbott Laboratories (US), Roche Diagnostics (CH), Siemens Healthineers (DE), Thermo Fisher Scientific (US), Becton Dickinson and Company (US), Ortho Clinical Diagnostics (US), Grifols (ES), Bio-Rad Laboratories (US), Hologic (US)</p>

    Market Trends

    The Blood Screening Market is currently experiencing a transformative phase, driven by advancements in technology and an increasing emphasis on preventive healthcare. The integration of innovative diagnostic tools and methodologies is reshaping the landscape, allowing for more accurate and efficient detection of blood-borne pathogens and diseases. This evolution is further propelled by rising awareness among healthcare providers and patients regarding the importance of early diagnosis and treatment. As a result, the market is witnessing a surge in demand for comprehensive blood screening solutions that can cater to diverse healthcare settings, from hospitals to outpatient clinics. Moreover, regulatory frameworks are evolving to support the adoption of new technologies in blood screening. Governments and health organizations are prioritizing the establishment of stringent guidelines to ensure the safety and efficacy of blood screening processes. This regulatory support, coupled with ongoing research and development efforts, is likely to enhance the overall quality of blood screening services. The Blood Screening Market appears poised for sustained growth, as stakeholders continue to invest in innovative solutions that address the complexities of modern healthcare needs. The future landscape may be characterized by a greater emphasis on personalized medicine and tailored screening protocols, reflecting the dynamic nature of this vital sector.

    Technological Advancements

    The Blood Screening Market is witnessing rapid technological innovations that enhance diagnostic accuracy and efficiency. Emerging tools, such as next-generation sequencing and automated analyzers, are streamlining processes and reducing turnaround times. These advancements not only improve patient outcomes but also facilitate the detection of a broader range of pathogens.

    Regulatory Support

    Regulatory bodies are increasingly focusing on establishing robust frameworks to ensure the safety and effectiveness of blood screening practices. This support is crucial for fostering innovation and encouraging the adoption of new technologies. Enhanced regulations may lead to improved standards in testing and quality assurance.

    Growing Preventive Healthcare

    There is a noticeable shift towards preventive healthcare, with more emphasis on early detection and management of diseases. This trend is driving demand for comprehensive blood screening services, as healthcare providers recognize the importance of proactive measures in improving patient health outcomes.

    Blood Screening Market Market Drivers

    Regulatory Framework Enhancements

    The Blood Screening Market is significantly influenced by the evolving regulatory landscape. Governments and health authorities are increasingly implementing stringent regulations to ensure the safety and efficacy of blood screening processes. These regulations often mandate comprehensive testing protocols for blood products, thereby driving the demand for advanced screening technologies. For instance, the introduction of new guidelines for blood safety has led to an uptick in the adoption of automated screening systems. This regulatory push is expected to propel the Blood Screening Market forward, as compliance with these standards necessitates investment in innovative screening solutions.

    Expansion of Healthcare Infrastructure

    The expansion of healthcare infrastructure, particularly in developing regions, serves as a vital driver for the Blood Screening Market. As countries invest in improving their healthcare systems, the establishment of new hospitals and diagnostic centers increases the demand for blood screening services. This growth is particularly evident in regions where access to healthcare has historically been limited. The World Health Organization has reported a significant increase in healthcare spending in these areas, which is likely to enhance the availability of blood screening technologies. Consequently, the Blood Screening Market is expected to benefit from this infrastructural development, as more facilities seek to implement comprehensive blood screening programs.

    Increasing Prevalence of Infectious Diseases

    The rising incidence of infectious diseases is a crucial driver for the Blood Screening Market. As the world witnesses a surge in conditions such as hepatitis, HIV, and other blood-borne pathogens, the demand for effective blood screening solutions intensifies. According to recent estimates, the prevalence of hepatitis C alone affects millions, necessitating robust screening measures. This trend compels healthcare providers to adopt advanced blood screening technologies to ensure patient safety and effective disease management. Consequently, the Blood Screening Market is likely to experience substantial growth as healthcare systems prioritize the implementation of comprehensive screening protocols to combat these infectious threats.

    Technological Innovations in Blood Screening

    Technological advancements play a pivotal role in shaping the Blood Screening Market. Innovations such as nucleic acid testing (NAT) and next-generation sequencing (NGS) have revolutionized the accuracy and efficiency of blood screening processes. These technologies enable the detection of pathogens at lower levels, enhancing the safety of blood transfusions. The market for blood screening technologies is projected to grow significantly, with estimates suggesting a compound annual growth rate (CAGR) of over 8% in the coming years. As healthcare providers increasingly adopt these cutting-edge solutions, the Blood Screening Market is poised for transformative growth, driven by the need for precision and reliability in screening practices.

    Rising Awareness of Blood Donation and Screening

    The growing awareness surrounding the importance of blood donation and screening is a significant driver for the Blood Screening Market. Educational campaigns and initiatives by health organizations have led to increased public participation in blood donation drives. This heightened awareness not only encourages more individuals to donate blood but also emphasizes the necessity of thorough screening to ensure the safety of the blood supply. As a result, the demand for blood screening services is expected to rise, with projections indicating a potential increase in screening volumes by 15% over the next few years. This trend underscores the critical role of public health education in bolstering the Blood Screening Market.

    Market Segment Insights

    By Technology: Nucleic Acid Amplification Test (Largest) vs. Next-Generation Sequencing (Fastest-Growing)

    <p>The Blood Screening Market showcases diverse technologies, primarily dominated by Nucleic Acid Amplification Tests (NAAT), which account for a significant portion of the market share. NAAT's effectiveness in detecting pathogens with high sensitivity has made it a preferred choice among healthcare providers. Enzyme-Linked Immunosorbent Assay (ELISA), while important, has a smaller share in comparison, reflecting its specific application niches within blood testing. Meanwhile, Next-Generation Sequencing (NGS) is rapidly gaining traction, attracting considerable attention for its comprehensive and detailed analysis capabilities. The growth trends in this segment indicate a robust upward trajectory, fueled by technological advancements and increasing awareness of infectious diseases. NGS is regarded as the fastest-growing method due to its ability to handle multiplex assays and provide rapid, accurate results. The rising incidence of viruses and a growing emphasis on precision medicine are primary drivers propelling these technologies' acceptance and market expansion in blood screening applications.</p>

    <p>Technology: Nucleic Acid Amplification Test (Dominant) vs. Next-Generation Sequencing (Emerging)</p>

    <p>Nucleic Acid Amplification Tests (NAAT) represent the dominant technology in the Blood Screening Market due to their unmatched sensitivity and specificity in detecting nucleic acids from pathogens. Their widespread adoption in clinical settings underscores their reliability and efficiency, making them essential for various infectious disease diagnostics. In contrast, Next-Generation Sequencing (NGS) is emerging as a key player in the market, capitalizing on its ability to provide detailed genomic insights. With its growing capacity to perform large-scale genomic analyses at reduced costs and improved turnaround times, NGS is positioned to revolutionize the landscape of blood screening, particularly in identifying complex and rare infections, thereby complementing the established NAAT technology.</p>

    By Product & Services: Reagents (Largest) vs. Instruments (Fastest-Growing)

    <p>In the Blood Screening Market, 'Reagents' hold the largest share, dominating the landscape with their essential role in various testing procedures. They are critical for the accuracy and reliability of blood screening results, which underscores their importance in clinical settings. In contrast, 'Instruments' are emerging as a significant player, experiencing rapid growth as advancements in technology drive innovation in blood screening solutions. This segment is becoming increasingly vital in enhancing efficiency and accuracy in diagnostic laboratories. The growth trends in the Blood Screening Market are being significantly influenced by the rising prevalence of blood-borne diseases and an increase in awareness regarding early diagnosis. Additionally, technological advancements in instruments, including automation and digitalization, are propelling the expansion of this segment. As healthcare institutions seek to upgrade their capabilities, the demand for innovative blood screening instruments is expected to surge, further solidifying their position in the market for the foreseeable future.</p>

    <p>Reagents (Dominant) vs. Instruments (Emerging)</p>

    <p>Reagents play a dominant role in the Blood Screening Market due to their essential function in the testing process. They facilitate the detection of various pathogens and markers in blood samples, making them indispensable for accurate diagnostics. The continued reliance on reliable reagents amidst growing health concerns further reinforces their market position. On the other hand, instruments are emerging as a critical component of blood screening solutions. The increasing integration of advanced technologies, such as automated testing systems and point-of-care devices, is enhancing the operational capabilities of diagnostic facilities. This influx of innovative instruments is not only improving turnaround times but also elevating the accuracy of results, thereby positioning them as a rapidly growing segment in the industry.</p>

    By End User: Hospitals (Largest) vs. Clinics (Fastest-Growing)

    <p>In the Blood Screening Market, the distribution of end users reveals that hospitals hold the largest share, driven by their comprehensive healthcare services and advanced diagnostic capabilities. Clinics, by contrast, are rapidly emerging, adopting blood screening technologies for faster diagnosis and treatment, reflecting a growing healthcare trend that prioritizes patient-centric services. The 'Others' category, which includes laboratories and research facilities, plays a supportive role but lacks the prominence of the primary segments.</p>

    <p>End Users: Hospitals (Dominant) vs. Clinics (Emerging)</p>

    <p>Hospitals dominate the Blood Screening Market as they are equipped with sophisticated diagnostic tools and are often the primary settings for extensive blood testing. Their established infrastructure facilitates the integration of advanced screening techniques. Conversely, clinics are emerging as significant players, driven by increased patient footfall and the need for quicker, more accessible testing solutions. These smaller, more agile facilities are adapting rapidly to technological advancements, making them appealing alternatives for routine screenings. The increase in preventive healthcare initiatives further strengthens the position of clinics in this dynamic market.</p>

    Get more detailed insights about Blood Screening Market Research Report - Forecast till 2035

    Regional Insights

    North America : Market Leader in Innovation

    North America is the largest market for blood screening, holding approximately 45% of the global share. The region's growth is driven by advanced healthcare infrastructure, increasing prevalence of blood-borne diseases, and stringent regulatory frameworks. The demand for rapid and accurate diagnostic tests is also on the rise, fueled by technological advancements and a growing focus on preventive healthcare. The United States is the leading country in this market, followed by Canada. Major players like Abbott Laboratories, Thermo Fisher Scientific, and Becton Dickinson are headquartered here, contributing to a competitive landscape. The presence of these key players ensures continuous innovation and development of new screening technologies, enhancing market growth and improving patient outcomes.

    Europe : Regulatory Frameworks Drive Growth

    Europe is the second-largest market for blood screening, accounting for about 30% of the global market share. The region benefits from robust healthcare systems and increasing investments in diagnostic technologies. Regulatory bodies are actively promoting blood safety and screening standards, which further drives market growth. The rising incidence of infectious diseases and the need for early diagnosis are also significant demand drivers in this region. Germany and the UK are the leading countries in the European blood screening market, with a strong presence of key players like Roche Diagnostics and Siemens Healthineers. The competitive landscape is characterized by collaborations and partnerships among companies to enhance product offerings. The focus on research and development is also prominent, ensuring that Europe remains at the forefront of blood screening innovations.

    Asia-Pacific : Rapid Growth and Expansion

    Asia-Pacific is witnessing rapid growth in the blood screening market, holding approximately 20% of the global share. The region's expansion is driven by increasing healthcare expenditure, rising awareness of blood-related diseases, and a growing population. Governments are investing in healthcare infrastructure and promoting initiatives for early disease detection, which are significant catalysts for market growth. China and India are the leading countries in this region, with a burgeoning demand for advanced diagnostic solutions. The competitive landscape is evolving, with both local and international players like Grifols and Bio-Rad Laboratories expanding their presence. The focus on affordable and accessible healthcare solutions is shaping the market dynamics, making Asia-Pacific a key player in the global blood screening landscape.

    Middle East and Africa : Untapped Potential in Healthcare

    The Middle East and Africa region is gradually emerging in the blood screening market, holding about 5% of the global share. The growth is primarily driven by increasing investments in healthcare infrastructure and rising awareness of blood safety. Governments are implementing policies to enhance healthcare access, which is expected to boost demand for blood screening technologies in the coming years. Countries like South Africa and the UAE are leading the market, with a growing number of healthcare facilities adopting advanced diagnostic solutions. The competitive landscape is characterized by a mix of local and international players, focusing on tailored solutions to meet regional needs. The presence of key players is gradually increasing, paving the way for future growth in this untapped market.

    Key Players and Competitive Insights

    The Blood Screening Market is currently characterized by a dynamic competitive landscape, driven by technological advancements, increasing prevalence of blood-related diseases, and a growing emphasis on early diagnosis. Major players such as Abbott Laboratories (US), Roche Diagnostics (CH), and Siemens Healthineers (DE) are strategically positioned to leverage innovation and expand their market presence. Abbott Laboratories (US) focuses on enhancing its diagnostic capabilities through continuous product development, while Roche Diagnostics (CH) emphasizes partnerships to bolster its research and development efforts. Siemens Healthineers (DE) is investing in digital transformation initiatives, which collectively shape a competitive environment that prioritizes technological superiority and strategic collaborations.

    Key business tactics within the Blood Screening Market include localizing manufacturing and optimizing supply chains to enhance operational efficiency. The market appears moderately fragmented, with several key players exerting substantial influence. This structure allows for a competitive interplay where innovation and strategic partnerships are pivotal in maintaining market share and driving growth.

    In August 2025, Abbott Laboratories (US) announced the launch of a new blood screening platform designed to improve the accuracy and speed of infectious disease detection. This strategic move is likely to enhance Abbott's competitive edge by addressing the increasing demand for rapid diagnostics, thereby positioning the company favorably in a market that values efficiency and reliability.

    In September 2025, Roche Diagnostics (CH) entered into a collaboration with a leading biotechnology firm to develop next-generation blood screening assays. This partnership is indicative of Roche's commitment to innovation and suggests a strategic focus on expanding its product portfolio to meet evolving market needs. Such collaborations may enhance Roche's capabilities in delivering cutting-edge diagnostic solutions, further solidifying its market position.

    In July 2025, Siemens Healthineers (DE) unveiled a new AI-driven analytics tool aimed at optimizing blood screening processes. This initiative reflects Siemens' strategic emphasis on integrating artificial intelligence into its offerings, potentially revolutionizing how blood screening is conducted. The introduction of AI technologies may not only improve operational efficiencies but also enhance diagnostic accuracy, thereby attracting a broader customer base.

    As of October 2025, the Blood Screening Market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are increasingly shaping the competitive landscape, enabling companies to pool resources and expertise. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift underscores the importance of adaptability and forward-thinking strategies in navigating the complexities of the market.

    Key Companies in the Blood Screening Market market include

    Industry Developments

    June 2021: Grail, an American pharmaceutical and biotechnology company, has announced the release of the Galleri blood screening test, an advanced multi-cancer screening diagnostic that can detect the presence of multiple cancers. This test will assist the company in screening approximately 50 million people after its launch to obtain full FDA approval by 2023.

    May 2021: Tzar Labs, a molecular diagnostics company, and Epigeneres Biotechnology have announced the development of cancer tests for early detection. This test, which will be available by the end of 2023, will assist in determining the various stages of the disease. The company's accuracy rates for cancer screening tests are very high, and it has demonstrated results for all forms of cancer.

    October 2020: Siemens Healthineers has announced the availability of its laboratory-based total immunoglobulin test1 for identifying SARS-CoV-2 IgM and IgG immunoglobulin in the blood throughout the world. The ability to identify patients who have an adaptive immune response is made possible by the complete antibody test.

    .webp

    Future Outlook

    Blood Screening Market Future Outlook

    <p>The Blood Screening Market is projected to grow at a 10.2% CAGR from 2024 to 2035, driven by technological advancements, increasing disease prevalence, and rising health awareness.</p>

    New opportunities lie in:

    • <p>Development of AI-driven diagnostic tools for enhanced accuracy.</p>
    • <p>Expansion of mobile blood screening units in underserved regions.</p>
    • <p>Partnerships with telehealth platforms for remote screening services.</p>

    <p>By 2035, the Blood Screening Market is expected to be robust, driven by innovation and strategic partnerships.</p>

    Market Segmentation

    Blood Screening Market End User Outlook

    • Hospitals
    • Clinics
    • Others

    Blood Screening Market Technology Outlook

    • Nucleic Acid Amplification Test
    • Enzyme-Linked Immunosorbent Assay
    • Next-Generation Sequencing

    Blood Screening Market Product & Services Outlook

    • Reagents
    • Instruments

    Report Scope

    MARKET SIZE 20243.4(USD Billion)
    MARKET SIZE 20253.747(USD Billion)
    MARKET SIZE 20359.898(USD Billion)
    COMPOUND ANNUAL GROWTH RATE (CAGR)10.2% (2024 - 2035)
    REPORT COVERAGERevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    BASE YEAR2024
    Market Forecast Period2025 - 2035
    Historical Data2019 - 2024
    Market Forecast UnitsUSD Billion
    Key Companies ProfiledMarket analysis in progress
    Segments CoveredMarket segmentation analysis in progress
    Key Market OpportunitiesIntegration of advanced technologies enhances accuracy and efficiency in the Blood Screening Market.
    Key Market DynamicsTechnological advancements and regulatory changes drive innovation and competition in the blood screening market.
    Countries CoveredNorth America, Europe, APAC, South America, MEA

    FAQs

    What is the projected market valuation of the Blood Screening Market by 2035?

    The Blood Screening Market is projected to reach approximately 9.898 USD Billion by 2035.

    What was the market valuation of the Blood Screening Market in 2024?

    In 2024, the Blood Screening Market was valued at 3.4 USD Billion.

    What is the expected CAGR for the Blood Screening Market during the forecast period 2025 - 2035?

    The expected CAGR for the Blood Screening Market during the forecast period 2025 - 2035 is 10.2%.

    Which technology segment is anticipated to show significant growth in the Blood Screening Market?

    The Nucleic Acid Amplification Test segment is expected to grow from 1.2 USD Billion in 2024 to 3.5 USD Billion by 2035.

    What are the key products and services driving the Blood Screening Market?

    Reagents and instruments are key products, with reagents projected to grow from 1.5 USD Billion in 2024 to 4.5 USD Billion by 2035.

    Which end-user segment is likely to dominate the Blood Screening Market?

    Hospitals are likely to dominate the end-user segment, growing from 1.7 USD Billion in 2024 to 4.8 USD Billion by 2035.

    1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
      1. | 1.1 EXECUTIVE SUMMARY
      2. | | 1.1.1 Market Overview
      3. | | 1.1.2 Key Findings
      4. | | 1.1.3 Market Segmentation
      5. | | 1.1.4 Competitive Landscape
      6. | | 1.1.5 Challenges and Opportunities
      7. | | 1.1.6 Future Outlook
    2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
      1. | 2.1 MARKET INTRODUCTION
      2. | | 2.1.1 Definition
      3. | | 2.1.2 Scope of the study
      4. | | | 2.1.2.1 Research Objective
      5. | | | 2.1.2.2 Assumption
      6. | | | 2.1.2.3 Limitations
      7. | 2.2 RESEARCH METHODOLOGY
      8. | | 2.2.1 Overview
      9. | | 2.2.2 Data Mining
      10. | | 2.2.3 Secondary Research
      11. | | 2.2.4 Primary Research
      12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
      13. | | | 2.2.4.2 Breakdown of Primary Respondents
      14. | | 2.2.5 Forecasting Model
      15. | | 2.2.6 Market Size Estimation
      16. | | | 2.2.6.1 Bottom-Up Approach
      17. | | | 2.2.6.2 Top-Down Approach
      18. | | 2.2.7 Data Triangulation
      19. | | 2.2.8 Validation
    3. SECTION III: QUALITATIVE ANALYSIS
      1. | 3.1 MARKET DYNAMICS
      2. | | 3.1.1 Overview
      3. | | 3.1.2 Drivers
      4. | | 3.1.3 Restraints
      5. | | 3.1.4 Opportunities
      6. | 3.2 MARKET FACTOR ANALYSIS
      7. | | 3.2.1 Value chain Analysis
      8. | | 3.2.2 Porter's Five Forces Analysis
      9. | | | 3.2.2.1 Bargaining Power of Suppliers
      10. | | | 3.2.2.2 Bargaining Power of Buyers
      11. | | | 3.2.2.3 Threat of New Entrants
      12. | | | 3.2.2.4 Threat of Substitutes
      13. | | | 3.2.2.5 Intensity of Rivalry
      14. | | 3.2.3 COVID-19 Impact Analysis
      15. | | | 3.2.3.1 Market Impact Analysis
      16. | | | 3.2.3.2 Regional Impact
      17. | | | 3.2.3.3 Opportunity and Threat Analysis
    4. SECTION IV: QUANTITATIVE ANALYSIS
      1. | 4.1 Healthcare, BY Technology (USD Billion)
      2. | | 4.1.1 Nucleic Acid Amplification Test
      3. | | 4.1.2 Enzyme-Linked Immunosorbent Assay
      4. | | 4.1.3 Next-Generation Sequencing
      5. | 4.2 Healthcare, BY Product & Services (USD Billion)
      6. | | 4.2.1 Reagents
      7. | | 4.2.2 Instruments
      8. | 4.3 Healthcare, BY End User (USD Billion)
      9. | | 4.3.1 Hospitals
      10. | | 4.3.2 Clinics
      11. | | 4.3.3 Others
      12. | 4.4 Healthcare, BY Region (USD Billion)
      13. | | 4.4.1 North America
      14. | | | 4.4.1.1 US
      15. | | | 4.4.1.2 Canada
      16. | | 4.4.2 Europe
      17. | | | 4.4.2.1 Germany
      18. | | | 4.4.2.2 UK
      19. | | | 4.4.2.3 France
      20. | | | 4.4.2.4 Russia
      21. | | | 4.4.2.5 Italy
      22. | | | 4.4.2.6 Spain
      23. | | | 4.4.2.7 Rest of Europe
      24. | | 4.4.3 APAC
      25. | | | 4.4.3.1 China
      26. | | | 4.4.3.2 India
      27. | | | 4.4.3.3 Japan
      28. | | | 4.4.3.4 South Korea
      29. | | | 4.4.3.5 Malaysia
      30. | | | 4.4.3.6 Thailand
      31. | | | 4.4.3.7 Indonesia
      32. | | | 4.4.3.8 Rest of APAC
      33. | | 4.4.4 South America
      34. | | | 4.4.4.1 Brazil
      35. | | | 4.4.4.2 Mexico
      36. | | | 4.4.4.3 Argentina
      37. | | | 4.4.4.4 Rest of South America
      38. | | 4.4.5 MEA
      39. | | | 4.4.5.1 GCC Countries
      40. | | | 4.4.5.2 South Africa
      41. | | | 4.4.5.3 Rest of MEA
    5. SECTION V: COMPETITIVE ANALYSIS
      1. | 5.1 Competitive Landscape
      2. | | 5.1.1 Overview
      3. | | 5.1.2 Competitive Analysis
      4. | | 5.1.3 Market share Analysis
      5. | | 5.1.4 Major Growth Strategy in the Healthcare
      6. | | 5.1.5 Competitive Benchmarking
      7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
      8. | | 5.1.7 Key developments and growth strategies
      9. | | | 5.1.7.1 New Product Launch/Service Deployment
      10. | | | 5.1.7.2 Merger & Acquisitions
      11. | | | 5.1.7.3 Joint Ventures
      12. | | 5.1.8 Major Players Financial Matrix
      13. | | | 5.1.8.1 Sales and Operating Income
      14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
      15. | 5.2 Company Profiles
      16. | | 5.2.1 Abbott Laboratories (US)
      17. | | | 5.2.1.1 Financial Overview
      18. | | | 5.2.1.2 Products Offered
      19. | | | 5.2.1.3 Key Developments
      20. | | | 5.2.1.4 SWOT Analysis
      21. | | | 5.2.1.5 Key Strategies
      22. | | 5.2.2 Roche Diagnostics (CH)
      23. | | | 5.2.2.1 Financial Overview
      24. | | | 5.2.2.2 Products Offered
      25. | | | 5.2.2.3 Key Developments
      26. | | | 5.2.2.4 SWOT Analysis
      27. | | | 5.2.2.5 Key Strategies
      28. | | 5.2.3 Siemens Healthineers (DE)
      29. | | | 5.2.3.1 Financial Overview
      30. | | | 5.2.3.2 Products Offered
      31. | | | 5.2.3.3 Key Developments
      32. | | | 5.2.3.4 SWOT Analysis
      33. | | | 5.2.3.5 Key Strategies
      34. | | 5.2.4 Thermo Fisher Scientific (US)
      35. | | | 5.2.4.1 Financial Overview
      36. | | | 5.2.4.2 Products Offered
      37. | | | 5.2.4.3 Key Developments
      38. | | | 5.2.4.4 SWOT Analysis
      39. | | | 5.2.4.5 Key Strategies
      40. | | 5.2.5 Becton Dickinson and Company (US)
      41. | | | 5.2.5.1 Financial Overview
      42. | | | 5.2.5.2 Products Offered
      43. | | | 5.2.5.3 Key Developments
      44. | | | 5.2.5.4 SWOT Analysis
      45. | | | 5.2.5.5 Key Strategies
      46. | | 5.2.6 Ortho Clinical Diagnostics (US)
      47. | | | 5.2.6.1 Financial Overview
      48. | | | 5.2.6.2 Products Offered
      49. | | | 5.2.6.3 Key Developments
      50. | | | 5.2.6.4 SWOT Analysis
      51. | | | 5.2.6.5 Key Strategies
      52. | | 5.2.7 Grifols (ES)
      53. | | | 5.2.7.1 Financial Overview
      54. | | | 5.2.7.2 Products Offered
      55. | | | 5.2.7.3 Key Developments
      56. | | | 5.2.7.4 SWOT Analysis
      57. | | | 5.2.7.5 Key Strategies
      58. | | 5.2.8 Bio-Rad Laboratories (US)
      59. | | | 5.2.8.1 Financial Overview
      60. | | | 5.2.8.2 Products Offered
      61. | | | 5.2.8.3 Key Developments
      62. | | | 5.2.8.4 SWOT Analysis
      63. | | | 5.2.8.5 Key Strategies
      64. | | 5.2.9 Hologic (US)
      65. | | | 5.2.9.1 Financial Overview
      66. | | | 5.2.9.2 Products Offered
      67. | | | 5.2.9.3 Key Developments
      68. | | | 5.2.9.4 SWOT Analysis
      69. | | | 5.2.9.5 Key Strategies
      70. | 5.3 Appendix
      71. | | 5.3.1 References
      72. | | 5.3.2 Related Reports
    6. LIST OF FIGURES
      1. | 6.1 MARKET SYNOPSIS
      2. | 6.2 NORTH AMERICA MARKET ANALYSIS
      3. | 6.3 US MARKET ANALYSIS BY TECHNOLOGY
      4. | 6.4 US MARKET ANALYSIS BY PRODUCT & SERVICES
      5. | 6.5 US MARKET ANALYSIS BY END USER
      6. | 6.6 CANADA MARKET ANALYSIS BY TECHNOLOGY
      7. | 6.7 CANADA MARKET ANALYSIS BY PRODUCT & SERVICES
      8. | 6.8 CANADA MARKET ANALYSIS BY END USER
      9. | 6.9 EUROPE MARKET ANALYSIS
      10. | 6.10 GERMANY MARKET ANALYSIS BY TECHNOLOGY
      11. | 6.11 GERMANY MARKET ANALYSIS BY PRODUCT & SERVICES
      12. | 6.12 GERMANY MARKET ANALYSIS BY END USER
      13. | 6.13 UK MARKET ANALYSIS BY TECHNOLOGY
      14. | 6.14 UK MARKET ANALYSIS BY PRODUCT & SERVICES
      15. | 6.15 UK MARKET ANALYSIS BY END USER
      16. | 6.16 FRANCE MARKET ANALYSIS BY TECHNOLOGY
      17. | 6.17 FRANCE MARKET ANALYSIS BY PRODUCT & SERVICES
      18. | 6.18 FRANCE MARKET ANALYSIS BY END USER
      19. | 6.19 RUSSIA MARKET ANALYSIS BY TECHNOLOGY
      20. | 6.20 RUSSIA MARKET ANALYSIS BY PRODUCT & SERVICES
      21. | 6.21 RUSSIA MARKET ANALYSIS BY END USER
      22. | 6.22 ITALY MARKET ANALYSIS BY TECHNOLOGY
      23. | 6.23 ITALY MARKET ANALYSIS BY PRODUCT & SERVICES
      24. | 6.24 ITALY MARKET ANALYSIS BY END USER
      25. | 6.25 SPAIN MARKET ANALYSIS BY TECHNOLOGY
      26. | 6.26 SPAIN MARKET ANALYSIS BY PRODUCT & SERVICES
      27. | 6.27 SPAIN MARKET ANALYSIS BY END USER
      28. | 6.28 REST OF EUROPE MARKET ANALYSIS BY TECHNOLOGY
      29. | 6.29 REST OF EUROPE MARKET ANALYSIS BY PRODUCT & SERVICES
      30. | 6.30 REST OF EUROPE MARKET ANALYSIS BY END USER
      31. | 6.31 APAC MARKET ANALYSIS
      32. | 6.32 CHINA MARKET ANALYSIS BY TECHNOLOGY
      33. | 6.33 CHINA MARKET ANALYSIS BY PRODUCT & SERVICES
      34. | 6.34 CHINA MARKET ANALYSIS BY END USER
      35. | 6.35 INDIA MARKET ANALYSIS BY TECHNOLOGY
      36. | 6.36 INDIA MARKET ANALYSIS BY PRODUCT & SERVICES
      37. | 6.37 INDIA MARKET ANALYSIS BY END USER
      38. | 6.38 JAPAN MARKET ANALYSIS BY TECHNOLOGY
      39. | 6.39 JAPAN MARKET ANALYSIS BY PRODUCT & SERVICES
      40. | 6.40 JAPAN MARKET ANALYSIS BY END USER
      41. | 6.41 SOUTH KOREA MARKET ANALYSIS BY TECHNOLOGY
      42. | 6.42 SOUTH KOREA MARKET ANALYSIS BY PRODUCT & SERVICES
      43. | 6.43 SOUTH KOREA MARKET ANALYSIS BY END USER
      44. | 6.44 MALAYSIA MARKET ANALYSIS BY TECHNOLOGY
      45. | 6.45 MALAYSIA MARKET ANALYSIS BY PRODUCT & SERVICES
      46. | 6.46 MALAYSIA MARKET ANALYSIS BY END USER
      47. | 6.47 THAILAND MARKET ANALYSIS BY TECHNOLOGY
      48. | 6.48 THAILAND MARKET ANALYSIS BY PRODUCT & SERVICES
      49. | 6.49 THAILAND MARKET ANALYSIS BY END USER
      50. | 6.50 INDONESIA MARKET ANALYSIS BY TECHNOLOGY
      51. | 6.51 INDONESIA MARKET ANALYSIS BY PRODUCT & SERVICES
      52. | 6.52 INDONESIA MARKET ANALYSIS BY END USER
      53. | 6.53 REST OF APAC MARKET ANALYSIS BY TECHNOLOGY
      54. | 6.54 REST OF APAC MARKET ANALYSIS BY PRODUCT & SERVICES
      55. | 6.55 REST OF APAC MARKET ANALYSIS BY END USER
      56. | 6.56 SOUTH AMERICA MARKET ANALYSIS
      57. | 6.57 BRAZIL MARKET ANALYSIS BY TECHNOLOGY
      58. | 6.58 BRAZIL MARKET ANALYSIS BY PRODUCT & SERVICES
      59. | 6.59 BRAZIL MARKET ANALYSIS BY END USER
      60. | 6.60 MEXICO MARKET ANALYSIS BY TECHNOLOGY
      61. | 6.61 MEXICO MARKET ANALYSIS BY PRODUCT & SERVICES
      62. | 6.62 MEXICO MARKET ANALYSIS BY END USER
      63. | 6.63 ARGENTINA MARKET ANALYSIS BY TECHNOLOGY
      64. | 6.64 ARGENTINA MARKET ANALYSIS BY PRODUCT & SERVICES
      65. | 6.65 ARGENTINA MARKET ANALYSIS BY END USER
      66. | 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY
      67. | 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY PRODUCT & SERVICES
      68. | 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
      69. | 6.69 MEA MARKET ANALYSIS
      70. | 6.70 GCC COUNTRIES MARKET ANALYSIS BY TECHNOLOGY
      71. | 6.71 GCC COUNTRIES MARKET ANALYSIS BY PRODUCT & SERVICES
      72. | 6.72 GCC COUNTRIES MARKET ANALYSIS BY END USER
      73. | 6.73 SOUTH AFRICA MARKET ANALYSIS BY TECHNOLOGY
      74. | 6.74 SOUTH AFRICA MARKET ANALYSIS BY PRODUCT & SERVICES
      75. | 6.75 SOUTH AFRICA MARKET ANALYSIS BY END USER
      76. | 6.76 REST OF MEA MARKET ANALYSIS BY TECHNOLOGY
      77. | 6.77 REST OF MEA MARKET ANALYSIS BY PRODUCT & SERVICES
      78. | 6.78 REST OF MEA MARKET ANALYSIS BY END USER
      79. | 6.79 KEY BUYING CRITERIA OF HEALTHCARE
      80. | 6.80 RESEARCH PROCESS OF MRFR
      81. | 6.81 DRO ANALYSIS OF HEALTHCARE
      82. | 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE
      83. | 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
      84. | 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE
      85. | 6.85 HEALTHCARE, BY TECHNOLOGY, 2024 (% SHARE)
      86. | 6.86 HEALTHCARE, BY TECHNOLOGY, 2024 TO 2035 (USD Billion)
      87. | 6.87 HEALTHCARE, BY PRODUCT & SERVICES, 2024 (% SHARE)
      88. | 6.88 HEALTHCARE, BY PRODUCT & SERVICES, 2024 TO 2035 (USD Billion)
      89. | 6.89 HEALTHCARE, BY END USER, 2024 (% SHARE)
      90. | 6.90 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
      91. | 6.91 BENCHMARKING OF MAJOR COMPETITORS
    7. LIST OF TABLES
      1. | 7.1 LIST OF ASSUMPTIONS
      2. | | 7.1.1
      3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
      4. | | 7.2.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      5. | | 7.2.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      6. | | 7.2.3 BY END USER, 2025-2035 (USD Billion)
      7. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
      8. | | 7.3.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      9. | | 7.3.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      10. | | 7.3.3 BY END USER, 2025-2035 (USD Billion)
      11. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
      12. | | 7.4.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      13. | | 7.4.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      14. | | 7.4.3 BY END USER, 2025-2035 (USD Billion)
      15. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
      16. | | 7.5.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      17. | | 7.5.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      18. | | 7.5.3 BY END USER, 2025-2035 (USD Billion)
      19. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
      20. | | 7.6.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      21. | | 7.6.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      22. | | 7.6.3 BY END USER, 2025-2035 (USD Billion)
      23. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
      24. | | 7.7.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      25. | | 7.7.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      26. | | 7.7.3 BY END USER, 2025-2035 (USD Billion)
      27. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
      28. | | 7.8.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      29. | | 7.8.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      30. | | 7.8.3 BY END USER, 2025-2035 (USD Billion)
      31. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
      32. | | 7.9.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      33. | | 7.9.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      34. | | 7.9.3 BY END USER, 2025-2035 (USD Billion)
      35. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
      36. | | 7.10.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      37. | | 7.10.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      38. | | 7.10.3 BY END USER, 2025-2035 (USD Billion)
      39. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
      40. | | 7.11.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      41. | | 7.11.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      42. | | 7.11.3 BY END USER, 2025-2035 (USD Billion)
      43. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
      44. | | 7.12.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      45. | | 7.12.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      46. | | 7.12.3 BY END USER, 2025-2035 (USD Billion)
      47. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
      48. | | 7.13.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      49. | | 7.13.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      50. | | 7.13.3 BY END USER, 2025-2035 (USD Billion)
      51. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
      52. | | 7.14.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      53. | | 7.14.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      54. | | 7.14.3 BY END USER, 2025-2035 (USD Billion)
      55. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
      56. | | 7.15.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      57. | | 7.15.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      58. | | 7.15.3 BY END USER, 2025-2035 (USD Billion)
      59. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
      60. | | 7.16.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      61. | | 7.16.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      62. | | 7.16.3 BY END USER, 2025-2035 (USD Billion)
      63. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
      64. | | 7.17.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      65. | | 7.17.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      66. | | 7.17.3 BY END USER, 2025-2035 (USD Billion)
      67. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
      68. | | 7.18.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      69. | | 7.18.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      70. | | 7.18.3 BY END USER, 2025-2035 (USD Billion)
      71. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
      72. | | 7.19.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      73. | | 7.19.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      74. | | 7.19.3 BY END USER, 2025-2035 (USD Billion)
      75. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
      76. | | 7.20.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      77. | | 7.20.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      78. | | 7.20.3 BY END USER, 2025-2035 (USD Billion)
      79. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
      80. | | 7.21.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      81. | | 7.21.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      82. | | 7.21.3 BY END USER, 2025-2035 (USD Billion)
      83. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
      84. | | 7.22.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      85. | | 7.22.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      86. | | 7.22.3 BY END USER, 2025-2035 (USD Billion)
      87. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
      88. | | 7.23.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      89. | | 7.23.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      90. | | 7.23.3 BY END USER, 2025-2035 (USD Billion)
      91. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
      92. | | 7.24.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      93. | | 7.24.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      94. | | 7.24.3 BY END USER, 2025-2035 (USD Billion)
      95. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
      96. | | 7.25.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      97. | | 7.25.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      98. | | 7.25.3 BY END USER, 2025-2035 (USD Billion)
      99. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
      100. | | 7.26.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      101. | | 7.26.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      102. | | 7.26.3 BY END USER, 2025-2035 (USD Billion)
      103. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
      104. | | 7.27.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      105. | | 7.27.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      106. | | 7.27.3 BY END USER, 2025-2035 (USD Billion)
      107. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
      108. | | 7.28.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      109. | | 7.28.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      110. | | 7.28.3 BY END USER, 2025-2035 (USD Billion)
      111. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
      112. | | 7.29.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      113. | | 7.29.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      114. | | 7.29.3 BY END USER, 2025-2035 (USD Billion)
      115. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
      116. | | 7.30.1 BY TECHNOLOGY, 2025-2035 (USD Billion)
      117. | | 7.30.2 BY PRODUCT & SERVICES, 2025-2035 (USD Billion)
      118. | | 7.30.3 BY END USER, 2025-2035 (USD Billion)
      119. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
      120. | | 7.31.1
      121. | 7.32 ACQUISITION/PARTNERSHIP
      122. | | 7.32.1

    Blood Screening Market Segmentation

    Blood Screening Technology Outlook (USD Billion, 2019-2030)

    • Nucleic Acid Amplification Test
    • Enzyme-Linked Immunosorbent Assay
    • Next-Generation Sequencing

    Blood Screening End User Outlook (USD Billion, 2019-2030)

    • Hospitals
    • Clinics
    • Others

    Blood Screening Product & Services Outlook (USD Billion, 2019-2030)

    • Reagents
    • Instrument

    Blood Screening Regional Outlook (USD Billion, 2019-2030)

    • North America Outlook (USD Billion, 2019-2030)

      • North America Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • North America Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • North America Blood Screening by Product & Services
        • Reagents
        • Instrument

      • US Outlook (USD Billion, 2019-2030)

      • US Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • US Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • US Blood Screening by Product & Services
        • Reagents
        • Instrument

      • CANADA Outlook (USD Billion, 2019-2030)

      • CANADA Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • CANADA Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • CANADA Blood Screening by Product & Services
        • Reagents
        • Instrument

    • Europe Outlook (USD Billion, 2019-2030)

      • Europe Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Europe Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Europe Blood Screening by Product & Services
        • Reagents
        • Instrument

      • Germany Outlook (USD Billion, 2019-2030)

      • Germany Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Germany Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Germany Blood Screening by Product & Services
        • Reagents
        • Instrument

      • France Outlook (USD Billion, 2019-2030)

      • France Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • France Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • France Blood Screening by Product & Services
        • Reagents
        • Instrument

      • UK Outlook (USD Billion, 2019-2030)

      • UK Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • UK Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • UK Blood Screening by Product & Services
        • Reagents
        • Instrument

      • ITALY Outlook (USD Billion, 2019-2030)

      • ITALY Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • ITALY Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • ITALY Blood Screening by Product & Services
        • Reagents
        • Instrument

      • SPAIN Outlook (USD Billion, 2019-2030)

      • Spain Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Spain Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Spain Blood Screening by Product & Services
        • Reagents
        • Instrument

      • Rest Of Europe Outlook (USD Billion, 2019-2030)

      • Rest Of Europe Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • REST OF EUROPE Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • REST OF EUROPE Blood Screening by Product & Services
        • Reagents
        • Instrument

    • Asia-Pacific Outlook (USD Billion, 2019-2030)

      • Asia-Pacific Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Asia-Pacific Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Asia-Pacific Blood Screening by Product & Services
        • Reagents
        • Instrument

      • China Outlook (USD Billion, 2019-2030)

      • China Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • China Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • China Blood Screening by Product & Services
        • Reagents
        • Instrument

      • Japan Outlook (USD Billion, 2019-2030)

      • Japan Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Japan Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Japan Blood Screening by Product & Services
        • Reagents
        • Instrument

      • India Outlook (USD Billion, 2019-2030)

      • India Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • India Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • India Blood Screening by Product & Services
        • Reagents
        • Instrument

      • Australia Outlook (USD Billion, 2019-2030)

      • Australia Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Australia Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Australia Blood Screening by Product & Services
        • Reagents
        • Instrument

      • Rest of Asia-Pacific Outlook (USD Billion, 2019-2030)

      • Rest of Asia-Pacific Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Rest of Asia-Pacific Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Rest of Asia-Pacific Blood Screening by Product & Services
        • Reagents
        • Instrument

    • Rest of the World Outlook (USD Billion, 2019-2030)

      • Rest of the World Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Rest of the World Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Rest of the World Blood Screening by Product & Services
        • Reagents
        • Instrument

      • Middle East Outlook (USD Billion, 2019-2030)

      • Middle East Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Middle East Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Middle East Blood Screening by Product & Services
        • Reagents
        • Instrument

      • Africa Outlook (USD Billion, 2019-2030)

      • Africa Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Africa Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Africa Blood Screening by Product & Services
        • Reagents
        • Instrument

      • Latin America Outlook (USD Billion, 2019-2030)

      • Latin America Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Latin America Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Latin America Blood Screening by Product & Services
        • Reagents
        • Instrument

     

    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Related Reports

    Regional Reports
    Country Reports

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization ✓ ✓ ✓
    Direct Access to Analyst ✓ ✓ ✓
    Deliverable Format ✓ ✓ ✓
    Platform Access ✗ ✗ ✓
    Discount on Next Purchase 10% 15% 15%
    Printable Versions ✗ ✗ ✓